Reven Pharmaceuticals, based in Westminster, CO, is a cutting-edge biopharmaceutical company focused on developing innovative pharmacological solutions that target the root cause of diseases by restoring immune system homeostasis. Their flagship product, RJX, is a stand-alone drug formulated to impact various disease indications stemming from inflammation, from cancer to cardiovascular disease.
Founded by co-founder and CSO Michael Volk, Reven Pharmaceuticals aims to revolutionize the healthcare industry by introducing a new generation of medications that address unmet medical needs and improve patient outcomes. With a strong emphasis on social accountability and technological advancements, Reven is at the forefront of driving advancements in the hypoxia market and beyond.
Generated from the website